• Return to Headlines

Albany Molecular Research is Among the Companies in the Life Sciences Tools & Services Industry With the Highest Debt to EBITDA Ratio (AMRI, TMO, QGEN, CRL, PKI)

By Nick Russo

Below are the three companies in the Life Sciences Tools & Services industry with the highest debt to EBITDA ratios. This ratio indicates how many years of EBITDA would be necessary in order to pay back all the debt (assuming Debt and EBITDA are constant). Typically, this ratio is considered to be alarming when it is greater than 3.0 but this can vary and should be looked at within the context of the industry.

Albany Molecular Research ranks highest with a a debt to EBITDA ratio of 19.7. Thermo Fisher Scientific is next with a a debt to EBITDA ratio of 4.0. QIAGEN ranks third highest with a a debt to EBITDA ratio of 3.5.

Charles River Laboratories follows with a a debt to EBITDA ratio of 3.4, and PerkinElmer rounds out the top five with a a debt to EBITDA ratio of 2.6.

SmarTrend recommended that subscribers consider buying shares of Albany Molecular Research on April 13th, 2017 as our technology indicated a new Uptrend was in progress when shares hit $15.39. Since that recommendation, shares of Albany Molecular Research have risen 31.1%. We continue to monitor Albany Molecular Research for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately.

Keywords: highest debt to ebitda ratio albany molecular research thermo fisher scientific qiagen charles river laboratories perkinelmer

Ticker(s): AMRI TMO QGEN CRL PKI